Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 11 of 11 for “"Miglustat"”.
-
Μελέτη των γονιδίων NPC-1 και NPC-2, τα οποία σχετίζονται με τη νόσο Niemann-Pick τύπου C, σε επιλεγμένες υποομάδες του ελληνικού πληθυσμού
… NPC patient was entered to early treatment with miglustat and has presented no overt neurological impairment after 11.5 years. Conclusions: Sequence variations of NPC genes were genotyped for first time in Greek individuals. The frequency and the type of the exonic polymorphisms observed in this …
-
Juvenile GM2 Gangliosidosis: A Model for Investigation of Small-molecule Therapies for Lysosomal Storage Diseases
… studied substrate reduction therapy (SRT), with miglustat, in a phase I/II clinical trial to assess its pharmacokinetics (PK), safety, tolerability in infantile and jGM2. Miglustat showed a PK profile similar to the one found in adult patients. The drug was found to be safe and well-tolerated in …
-
Niemann-Pick type c disease: pathogenesis and therapy
… pathologies as well as in combination with miglustat reduced levels of neuroinflammation in the mouse model. Furthermore, the cyclodextrin analogue Crysmeb was also examined as a novel therapy for NPC, and was found to have significant survival benefits as compared to HPβCD, the cyclodextrin …
-
Targeting host cell processing glucosidase activity as a potential strategy for reducing viral replication
… efficacy of N-butyl-deoxynojirimycin (NB-DNJ, Miglustat, Zavesca) against a broad spectrum of viruses including bovine viral diarrhoea virus (BVDV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) is attributed to the disruption of viral envelope glycoprotein formation through …
-
Dysregulation of cholesterol homeostasis
… I also show that treatment of SLOS cells with miglustat, an established therapy for NPC, ameliorates the NPC-like cellular phenotype and thus may have therapeutic benefit in SLOS. The incidence of both SLOS and NPC has been the subject of debate. Thus, using data generated from massively …
-
Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
… Recently the glycosphingolipid inhibitor miglustat was found to be effective in the treatment of myeloma bone disease. Eliglustat is small molecule drug that inhibits glucosylceramide synthase and is approved by the Food and Drug Administration for the treatment of Gaucher's Disease. …
-
Pharmacological approaches for lysosomal storage diseases
… ADLL synergised with the standard of care drug, miglustat. Altered energy metabolism was implicated as the mechanism of action in Npc1<sup>-/-</sup> mice. A neuroprotective effect of ADLL was also demonstrated in a mouse model of GM2 gangliosidosis (Sandhoff disease mouse) with differential …
-
Investigation into the pathogenesis and behaviour of two disorders of cholesterol homeostasis
… highlighted when the cells were treated with miglustat, the only approved therapy for NPC. However, the main pathway apparently affected by this drug in both SLOS and NPC was cell proliferation.</p>
-
Discovering genetic modifiers in Niemann-Pick Disease Type C
… a wide spectrum of causative NPC1 mutations. Miglustat (Zavesca) is the only approved therapy for NPC, and while it has been shown to improve clinical outcomes it is not a cure. To study the genetic architecture of NPC, including the clinical and genetic heterogeneity seen in this patient …
-
Peptides as therapeutics
… cellular inhibition than NB-DNJ (N-butyl DNJ; Miglustat), the CPP construct 6-[N-(1-deoxynojirimycino)]-hexanoyl-TAT showed comparable activity and the ER retaining construct 6-[N-(1-deoxynojirimycino)]-hexanoyl-KDEL showed a small but significant increase in activity following long-term …
-
Estudo dos mecanismos inflamatórios e de dano oxidativo em pacientes portadores de Niemann-Pick tipo C : efeito in vivo do miglustate e in vitro de β-ciclodextrina nanoparticulada, N-acetilcisteína e coenzima Q10
… pouco se sabe sobre o efeito do tratamento com miglustate (N-butil-desoxinojirimicina) sobre o estresse oxidativo e inflamação, além da correlação com a melhora no dano neurológico observado nesses pacientes. Considerando que os marcadores de estresse oxidativo e inflamação tem se mostrado alvos …